Many cardiovascular disease states end in progressive heart failure. Changes in intracellular calcium handling, including a reduced activity of the sarcoplasmic reticulum calcium pump (SERCA), contribute to this contractile dysfunction. As the regulatory protein phospholamban can inhibit the calcium pump, we evaluated it as a potential target to improve cardiac function. In this study, we describe a recombinant antibody-based protein (PLN-Ab) that binds to the cytoplasmic domain of phospholamban. Fluorescence resonance energy transfer (FRET) studies suggest that PLN-Ab mimics the effects of phospholamban phosphorylation. PLN-Ab accelerated the decay of the calcium transient when expressed in neonatal rat and adult mouse ventricular cardiac myocytes. In addition, direct injection of adenovirus encoding PLN-Ab into the diabetic mouse heart enhanced contractility when measured in vivo by echo cardiography and in ex vivo Langendorff perfused hearts. The PLN-Ab provides a novel therapeutic approach to improving contractility through in vivo expression of an antibody inside cardiac myocytes.
hospholamban (PLN) plays a crucial role in the physiological regulation of cardiac contractility. By inhibiting the calcium pump of the sarcoplasmic reticulum (SERCA), phospholamban reduces diastolic calcium uptake into the sarcoplasmic reticulum (SR) and hence the amount of SR calcium available for the next contraction. The inhibition of SERCA can be relieved by cyclic AMP-mediated phosphorylation of phospholamban, one of the components by which β-adrenergic stimulation increases contractility (1) . Indeed, complete ablation of phospholamban [PLN (−/−) mice] greatly enhances contractility of the heart, not only under normal physiological conditions, but also under pathological conditions where contractility is normally depressed (2) (3) (4) . In many cardiomyopathic states, the effect of phospholamban on contractility may be exaggerated by a decrease in SERCA expression relative to phospholamban in addition to a reduction in the phosphorylated state of phospholamban (5) (6) (7) . These studies suggest that directly modifying the interaction of SERCA with phospholamban may be therapeutically advantageous in improving contractility.
Although the ablation of phospholamban represents the most extreme example of modification of the SERCA-phospholamban interaction, it is impractical as a therapy in adults and has recently been implicated as a cause of heart failure in humans (8) . Even phospholamban mutations, which do not directly influence the interaction of SERCA and phospholamban, may have unforeseen consequences, indirectly contributing to the development of heart failure (9) . A more novel approach, avoiding mutations in phospholamban altogether, is the use of an antibody specifically targeted to the cytoplasmic portion of phospholamban. Previous studies have indicated the feasibility of using antibodies directed against phospholamban for improving SERCA function (10, 11) ; however these antibodies could only be used in isolated sarcoplasmic reticulum vesicles or in digitonin-permeabilized cardiac myocytes and are impractical for use in vivo. In the current study, we describe the development of a recombinant single chain antibody (PLN-Ab) developed from avian heavy and light variable IgY chains that specifically targets phospholamban and increases the activity of SERCA. Furthermore, this antibody can be expressed in vivo using adenoviral vectors and can modify contractility under both physiological and pathological conditions. This is the first reported use of an antibody expressed in vivo in cardiac muscle as a therapeutic agent aimed at improving contractile function.
METHODS

Phage display
To induce an antibody response, a chicken was immunized with a synthetic peptide containing the amino acid sequence of positions 3-19 of human phospholamban, which spans most of the cytoplasmic domain of phospholamban (cPln) and includes the phosphorylation sites Ser16 and Thr17. Bone marrow and spleen from the immunized chicken were harvested 54 days after primary immunization. After isolation of mRNA, RT-PCR was used to amplify the genes for the antibody variable regions of both IgY light (primers: 5′-ggaagatctagaggactgacctaggacggtcagg-3′ and 5′-gtggcccaggcggccctgactcagccgtcctcggtgtc-3′) and heavy chains (primers: 5′-ctggccggcctggccactagtggaggagacgatgacttcggtcc-3′ and 5′-ggtcagtcctctagatcttccggcggtggtggcagctccggtggtggcggttccgccgtgacgttggacgag-3′). The two PCR products were combined and PCR overlap extended into a single PCR product (primers: 5′-gaggaggaggaggaggaggtggcccaggcggccctgactcag-3′ and 5′-gaggaggaggaggaggaggagctggccggcctggccactagtggagg-3′). When expressed as a protein, this construct contains randomly combined light and heavy chain variable region representing the IgY repertoire of the chicken connected by a short linker. The genes encoding the variable regions of the heavy and light chain of the chicken IgY were cloned into a phagemid expression vector (pComb3H), resulting in a fusion of the single chain antibody product to the filamentous phage coat protein III (12) . When expressed in XL1-Blue bacterial cells and rescued with helper phage, the phage library (consisting of ~5×10 7 independent clones) displayed the single chain antibodies as fusion proteins on the viral surface. To select for phospholamban-binders, the phages were incubated in polystyrol tubes coated with BSA cross-linked phospholamban peptide. To enrich for phospholamban binding phages, six rounds of panning were performed. Enrichment of phospholamban binding phages was confirmed by a phage binding ELISA. The selected library was subcloned into a bacterial expression plasmid (pARA), which introduced a His (6) -tag at the N terminus for protein purification and a hemagglutinin (HA)-tag at the C terminus for protein detection (13) . Proteins from 20 independent clones were expressed, purified, and tested by ELISA. All proteins bound to the phospholamban peptide. The encoding DNA sequences were determined for five of the best phospholamban binders, which demonstrated that four of these proteins shared complete sequence identity (Fig. 1A) . The specificity of the binding was demonstrated in a competitive phage binding ELISA, in which the binding sites of the phospholamban peptide were blocked by the specific phospholamban antibody 2D12.
45 Ca-uptake, Indo 1 transients, edge detection measurements SR preparations were obtained from phospholamban-and SERCA-transfected HEK 293 cells; 10 cm dishes of HEK 293 cells were calcium phosphate plasmid transfected with 20 µg of pCMV-phospholamban and 10 µg of pCMV-SERCA and cultured for 3 days. SR vesicles were enriched by differential centrifugation and stored at -70°C. To test the effects of PLN-Ab and 2D12 on calcium transports, SR vesicles were incubated for 30 min with 10 µg of the respective antibody at 4°C. The uptake was initiated with 45 CaCl 2 (free calcium, 20 nM) and stopped after 15 min by filtration using a Millipore filtration apparatus and 0.45 µm nitrocellulose filters. Indo 1 transients in cardiac myocytes were obtained according to a recently published method (14) . Indo 1 transients were obtained from neonatal myocytes cotransfected with expression plasmids encoding the effector proteins phospholamban or phospholamban + PLN-Ab (15 µg input per electroporation cuvette) along with plasmid encoding green fluorescent protein (GFP, 4 µg input) to serve as a marker for living, transfected myocytes. Total DNA per transfection was kept constant with the empty expression plasmid, pCMV6. In three independent experiments, we analyzed neonatal myocytes (19-20 cells in each group) either expressing phospholamban alone or coexpressing phospholamban and PLN-Ab. For analysis of indo 1 data, representative transients from each cell were imported into an Excel spreadsheet and aligned and averaged by using the initial upstroke of the transient as a reference point. The effect of PLN-Ab on function in adult myocytes was determined by performing in vivo gene therapy (Hemodynamics) using adenovirus expression PLN-Ab or empty vector (control) mixed with green fluorescent protein (CMV driven GFP) expressing adenovirus (10:1 pfu/ml ratio) followed by myocyte isolation according to the method outlined in Belke et al. (15) . Indo 1 calcium transients and video edge detection were measured in separate aliquots of freshly isolated myocytes expressing GFP and coexpressing either PLN-Ab or the empty (control) vector. In some studies, myocytes were treated with isoproterenol (100 nM) to study the effect of β-adrenergic stimulation. The validity of this method of coinfecting myocytes with a mixture of different adenovirae in vivo to obtain dual expression was tested using adenovirus expressing nuclear localized Lac-Z and GFP (both CMV driven) mixed before injection at a ratio of 10:1 pfu, with GFP being the minor component at 1 x 10 10 pfu/ml. Under these conditions, >90% of GFP expressing myocytes also coexpressed nuclear localized Lac-Z.
Fluorescence resonance energy transfer
The CMV-driven fluorescence resonance energy transfer (FRET) construct (CcPlnY) contained aa2-27 of phospholamban cloned between Cyan fluorescent protein (CFP; N-terminal) and yellow fluorescent protein (YFP; C-terminal). This construct contains the phospholamban phosphorylation sites (Ser16, Thr17) and the hinge region (Pro21). For single cell measurements, the CcPlnY construct was electroporated into rat neonatal myocytes and the cells were attached to glass coverslips and incubated for 3 days to express CcPlnY. After incubation, CcPlnYexpressing cells were excited at 420 nm and the emission was recorded simultaneously at 485 ± 20 nm (CFP) and 535 ± 15 nm (YFP).
The effects of PLN-Ab, 2D12, rabbit anti chicken IgY (AB), and kinase A on CcPlnY were determined in vitro using the supernatants of the cellular lysates of HEK 293 cells expressing CcPlnY that were calcium phosphate plasmid transfected with 30 µg of pCMV-CcPlnY and cultured for 3 days. Harvested cells were homogenized in PBS (0.5 ml) and centrifuged at 14,000 rpm, and the supernatant was recovered and diluted in PBS (1:100) for FRET studies. Where indicated, 1 µg of the antibodies and PLN-Ab were added to 250 µl of CcPlnY-PBS solution. The catalytic domain of kinase A was used to phosphorylate CcPlnY. Fluorometric data are presented as YFP/CFP peak emission ratios of four independent measurements.
Hemodynamics
To study the effects of PLN-Ab expression in vivo, we cloned the gene coding for PLN-Ab (including the His and HA tags) into a replication-deficient adenoviral vector under control of the promoter-enhancer region of the human cytomegalovirus (Ad5CMVPLN-Ab). Gene transfer studies were performed in rats (n=11 PLN-Ab, n=7 control adenovirus without transgene, 2.5×10 10 pfu) via a catheter placed in the aortic root (16) . After 4 days, the left ventricular function was digitally recorded via a 2 French Millar pressure transducer. Left ventricular systolic pressure (LVSP), left ventricular end-diastolic pressure (LVEDP), and the maximum values of left ventricular pressure derivatives (+dP/dt, -dP/dt) were analyzed. Heart rates were similar between groups.
In vivo gene transfer in a disease state of depressed contractility was performed on mice that had been made diabetic by the injection (ip) of 200 mg/kg streptozotocin 3 wk before surgery. Diabetic mice had blood glucose levels in excess of 600 mg/dl, while nondiabetic mice had levels of 216 mg/dl (data not shown). Adenovirus was administered by direct injection into the left ventricular free wall (5 sites, 10 µl of 10 11 pfu/ml per site) using an insulin syringe with a 29 gauge needle. Mice were anesthetized with a ketamine (100 mg/kg)/Xylazine (8 mg/kg) mixture, intubated, and ventilated with room air. The heart was exposed by a lateral sternotomy at the level of the second intercostal space. A stitch was placed at the apex of the heart using an 8-O Ethalon suture to allow manipulation of the heart. Adenovirus was injected at five locations within the free wall of the left ventricle. This method allowed infection of 46 ± 2% of the volume of the heart (n=6, measured using AdvCMV nuclear localization sequence-βGal). After the thoracic cavity was closed, the mice were extubated and allowed to recover for 3 days.
Ex vivo function was measured in isolated perfused hearts 3 days after gene therapy. The aorta was cannulated, and a Langendorff perfusion was initiated with Krebs Henseleit buffer at a perfusion pressure of 55 mmHg. A small balloon was inserted into the left ventricle and inflated to an end diastolic pressure of 10 mmHg. Pressure development was recorded digitally by connecting the intraventricular balloon to the 2 French Millar. The hearts were paced at 400 bpm, and the resulting pressure waves were analyzed for pressure derivatives (+dP/dt, -dP/dt) and peak systolic pressure.
Echocardiography
For acquisition of in vivo cardiac functional data, we used an Apogee CX (ATL Interspec) echocardiography system. To optimize resolution and penetration with two-dimensional 2-D and M-mode imaging, the 9.0 MHz frequency was used at a minimum depth setting of 3 cm and a sector width of 40-50°. For pulsed-wave Doppler recordings, a sample size of 0.6 mm was used with a pulse repetition frequency of 5 kHz.
To improve near-field image quality, a standoff consisting of a short cylindrical polyethylene tube (wall thickness 1.1 mm, diameter 2.54 cm, height 1.59 cm) attached to the convex head of the transducer and filled with transmission gel was used. With the use of the standoff, the distance between the top of the transducer and the chest wall was ~0.66 cm. For image acquisition, the mouse was anesthetized with Avertin 2.5% (10 µl/g body weight). The mouse was placed in the left lateral decubitus position and the transducer placed on the left hemithorax. Care was taken not to apply excessive pressure on the chest to avoid bradycardia.
The 2-D parasternal short-axis view was used as a guide and a left ventricular M-mode tracing was obtained close to the papillary muscle level with a sweep speed of 100 mm/s. Pulsed Doppler tracings of the estimated left ventricular outflow tract velocity were obtained in a modified parasternal long-axis view at a sweep speed of 100 mm/s. M-mode and Doppler tracings were recorded on a videotape for off-line analysis on an Agilent Sonos 5500 system. After calibration of this system, left ventricular end-diastolic and end-systolic internal diameter (LVEDD/LVESD) was measured in three consecutive heart cycles using the American Society of Echocardiography leading-edge method (17) . Left ventricular fractional shortening was calculated as FS (%) = (LVEDD-LVESD)/LVEDDx100.
Using the mean aortic ejection time (ET) from three consecutive heart cycles obtained from the Doppler tracings of the left ventricular outflow tract, we calculated the velocity of circumferential fiber shortening (Vcf) as Vcf (circ/s) = (πLVEDD-πLVESD)/(ETxπLVEDD). Being sensitive to acute changes in loading conditions, mean Vcf provides an approach for assessing in vivo myocardial contractility under basal conditions without acute changes in arterial pressure (18) .
Statistics
Values are means ± SE. All two group comparisons were performed using an unpaired t test, while multigroup comparisons were performed using ANOVA (ANOVA) followed by a Student-Newman-Keuls post-hoc analysis.
RESULTS
Cloning of PLN-Ab
A chicken was injected with the cytoplasmic domain of phospholamban to evoke an immune response. To confirm the specificity of the response, chicken IgY antibodies isolated from the eggs (day 54 after the primary immunization) included primary antibodies specific for phospholamban in immunoblot studies. These antibodies could also activate SERCA-mediated SR calcium uptake in vitro (data not shown). Then the genes encoding the variable regions of the heavy and light chains of chicken IgY were fused into a construct and selected for binding to phospholamban using a phage display method. The resulting protein, which we termed "PLNAb," was subsequently analyzed for its affect on SR function when added to in vitro assays and when expressed in vivo. PLN-Ab bound to phospholamban in an immunoblot (Fig. 1B) and demonstrated the same capacity to activate SR calcium uptake (>3-fold over control, P<0.05) as the commercially available 2D12 anti-phospholamban antibody (Fig. 1C) .
Effects of PLN-Ab on the cytoplasmic domain of phospholamban
To further investigate how PLN-Ab enhances SR calcium uptake, we used a protein-based FRET method featuring the use of two color-shifted variants of green fluorescent protein (19, 20) . This method allows us to track changes in the distance between the two fluorescent proteins within living cells. The construct contains the cytoplasmic domain of phospholamban, which was cloned between the cyan (CFP) and yellow (YFP) variants of the fluorescent proteins (CcPlnY). Expression of the chimeric protein is driven by a CMV promoter. Being devoid of the phospholamban transmembrane domain, CcPlnY localizes in the cytoplasm as well as the nucleus. In single cell recordings (ratio of yellow to cyan fluorescence) of transfected neonatal myocytes expressing CcPlnY, FRET from CFP to YFP was reduced by adding isoproterenol (Fig. 2A) . This result, which suggests a phosphorylation-dependent change in the conformation of the cytoplasmic domain of phospholamban, was also present after the addition of forskolin (data not shown).
For in vitro measurements, a reduction of FRET was also observed when recombinant CcPlnY was phosphorylated using the catalytic subunit of protein kinase A (Fig. 2B) . PLN-Ab and 2D12 were able to mimic this change in FRET (P<0.05 vs. control), whereas a control antibody (AB) did not show an effect. These results suggest that exposure to PLN-Ab and related antibodies like 2D12 can mimic a phosphorylation-induced change in the conformation of phospholamban.
Expression of PLN-Ab in cardiac myocytes
Due to its avian origin, it was unclear whether PLN-Ab expressed in mammalian cardiac cells would translocate into the cytoplasm and preserve its functional effects on phospholamban. Adenoviral infection of isolated neonatal and adult myocytes confirmed the ability of cardiac myocytes to express this recombinant protein as determined by immunoblot (Fig. 3A) . After 3 days, phospholamban expression was not changed in comparison to control cells, indicating that PLN-Ab did not interfere with the expression of phospholamban. To study the cellular localization of PLN-Ab, a plasmid carrying a cDNA fusion of PLN-Ab and YFP (PLN-Ab-YFP) was transfected into neonatal rat cardiac myocytes, which were previously cultured for 1 wk.
YFP alone resulted in a pattern of expression that was diffuse and scattered. In contrast, PLNAb-YFP resulted in a cellular striation pattern in confocal images of transfected neonatal myocytes (Fig. 3B ) that is compatible with the localization of phospholamban in close proximity to sarcomeres in adult cardiac myocytes as previously shown (21) . The same pattern of PLN-Ab-YFP expression was observed in adult mouse cardiac myocytes after transfection in vivo by injection of the same naked DNA plasmid used to transfect neonates and subsequent myocyte isolation after 3 days (Fig. 3C) .
To investigate the effects on intracellular calcium handling, PLN-Ab was coexpressed with phospholamban in neonatal rat myocytes and calcium transients were recorded. Raw data for the indo 1 Ca 2+ transient is shown in Fig. 4A . Although the height of the transient (averaged for 20 observations) was slightly lower in myocytes transfected both phospholamban and PLN-Ab (1.31±0.04 vs. 1.40±0.06, phospholamban+PLN-Ab vs. phospholamban alone), this difference was not statistically significant. To compare transient kinetics, the averaged transients were normalized so that the height of the transient represents 100% (Fig. 4B) . Indo 1 transients from myocytes expressing PLN-Ab demonstrated an acceleration of calcium transients with a reduction in the half time (t 1/2 ) of diastolic calcium removal by 40% (Fig. 4C ). This observation is consistent with the binding of PLN-Ab to phospholamban and the interference with the normal interaction between phospholamban and SERCA.
Calcium transients were also measured in isolated adult mouse myocytes infected in vivo with a PLN-Ab/GFP adenovirus mixture. In comparison with the results obtained from neonatal myocytes, cardiac myocytes isolated from adult mice infected in vivo demonstrated a similar acceleration in the decline of the indo 1 calcium transient when the signals were normalized (Fig.  5A) , with a significant reduction (P<0.05) in the t 1/2 of calcium removal (Fig. 5B) . When myocyte shortening was measured using edge detection, both the extent of fractional shortening and the rate of relaxation were seen to increase significantly (P<0.05) in the PLN-Ab treated mice ( Fig. 5D and E) . The rate of contraction (Fig. 5C ) also tended to be higher in myocytes isolated from PLN-Ab treated mice; however, this difference was not significant.
In a separate series of experiments, we examined the effect of β-adrenergic stimulation with isoproterenol on the rate of decline of the indo 1 calcium transient in adult mouse myocytes (Fig.  6 ). As expected, isoproterenol significantly accelerated the rate of transient decay in the control group by decreasing the t 1/2 of calcium removal by 50% (Fig. 6B) . In contrast, isoproterenol treatment had only a slight effect in PLN-Ab group, accelerating the rate of decay by 15% (Fig.  6D) . These results indicate that treatment with PLN-Ab has a similar effect to treatment with isoproterenol on the decay of the calcium transient. This effect is not total however, since treatment of the PLB-Ab group with isoproterenol did lead to a sight acceleration of the decay transient.
In vivo gene therapy with PLN-Ab
To investigate whether adenovirus expressing PLN-Ab might be a useful tool for somatic gene transfer, concentrated and purified Ad5CMVPLN-Ab was delivered to the heart via the coronary arteries of rats, using a method described by Del Monte et al. (16) . Four days after the gene delivery, a left ventricular hemodynamic study was performed. Left ventricular function of animals treated with an adenovirus coding for PLN-Ab was compared with animals injected with a control adenovirus (no transgene). The speed of left ventricular relaxation (-dP/dt) as an index of diastolic relaxation was increased by 14% in PLN-Ab treated animals. Furthermore, the left ventricular end-diastolic pressure was decreased by 50%, suggesting an improved diastolic function in PLN-Ab treated animals (Fig. 7) . Other parameters such as the speed of contraction (+dP/dt) and systolic pressure (LVSP) tended to be higher in PLN-Ab treated animals, but these differences were not statistically significant.
To determine if PLN-Ab could improve contractile function in disease states where SR calcium handling is diminished, Ad5CMV PLN-Ab was injected directly into the left ventricular free wall of mice made diabetic with streptozotocin. Direct injection of adenovirus led to expression of the PLN-Ab transgene when examined by Western blot (Fig. 8A) . Under normal conditions, 3 wk of streptozotocin induced diabetes lead to a significant decrease in the rate of relaxation. Whereas the injection of empty adenovirus does not improve function in hearts isolated from diabetic mice, the injection of PLN-Ab significantly improved function, increasing the rate of relaxation nearly to the level observed in nondiabetic mice (Fig. 8B) . The rate of contraction (+dP/dt, Fig. 8C ) and peak systolic pressure (Fig. 8D ) also showed a similar improvement in diabetic mice injected with PLN-Ab adenovirus. This beneficial effect was not due to changes in the level of SERCA expression, as SERCA levels were similar between diabetic mice injected with PLN-Ab and empty adenovirus ( Fig. 9A and B) . Similarly, the level of phospholamban expression (both pentamer and monomer) did not differ between mice injected with PLN-Ab and empty adenovirus, although the monomeric form tended to be slightly elevated in PLN-Ab treated mice. These results suggest that PLN-Ab mediated its effects through its direct interaction with phospholamban, rather than indirectly altering the expression of SERCA or phospholamban to levels favoring increased Ca 2+ uptake by the sarcoplasmic reticulum.
Although gene therapy with PLN-Ab improved contractile function in the isolated ex vivo heart, we wanted to determine if a similar improvement in cardiac function could be observed in diabetic mice in vivo, using echo cardiography. Heart rate did not differ between the two groups (370±17, control vs. 393±23, PLN-Ab); however, two indicies of contractility, fractional shortening and the velocity of circumferential fiber shortening, were both significantly (P<0.05) higher in the PLN-Ab group (Fig. 10A and B) . These results support our ex vivo observations that PLN-Ab gene therapy improves contractile function under pathological conditions where contractile function is depressed.
DISCUSSION
Increasing contractility is the goal of a number of therapies aimed at improving cardiac output in a variety of disease states leading to heart failure. Pharmacological approaches that include β-adrenergic agonists and phosphodiesterase inhibitors mediate their contractile effects by increasing intracellular levels of cyclic AMP, leading to the activation of protein kinase A followed by phosphorylation of cardiac proteins like L-type calcium channels and phospholamban. Unfortunately, chronic stimulation of the adrenergic signal transduction pathway can be damaging to the heart, resulting in cardiac hypertrophy, heart failure, and subsequently increased mortality as observed in some genetic and pharmacologically induced animal models of adrenergic overstimulation (22, 23) . A more specific approach is to alter the activity of SERCA, either directly or indirectly, through modification of its inhibitory protein phospholamaban. Increasing SERCA activity through transgenic overexpression or adenoviral gene therapy leads to an improvement in function in cardiomyopathies where contractility is depressed (16, (24) (25) (26) . In view of the strong inhibitory effect of phospholamban on SERCA, it has also been targeted to modify SERCA activity. Reduction of phospholamban protein synthesis by adenoviral expression of phospholamban antisense was shown to be partially effective in improving contractility in isolated neonatal and adult cardiac myocytes (27, 28) . Another approach, leading to stronger effects on SR calcium transport and contractility in isolated cardiac myocytes, involves the expression of phospholamban mutants, which exert a dominant negative effect on wild-type phospholamban in isolated cardiac myocytes (3, 27, 29) . In the most extreme case, the ablation of phospholamban leads to increased SERCA activity and increased contractile force in both normal and some pathophysiological conditions (2, 3) . However, recent studies have shown that naturally occurring mutations in the human genome resulting in the ablation of phospholamban leads to the development of lethal dilated cardiomyopathy (8) . Furthermore, a recent study involving an arg → cys missense mutation at residue 9 of human phospholamban has also leads to heart failure (9). Expression of this mutant protein in mice recapitulates the human phenotype of dilated cardiomyopathy; however, the effect appears to be indirectly caused by tight PKA binding to the mutant phospholamban rather than the normal interaction of phospholamban with SERCA. Other mutations to phospholamban directed toward its region of protein-protein interaction with SERCA also leads to heart failure (30) . Given that mutations in phospholamban or its ablation may lead to heart failure, we sought to modify the activity of phospholamban by expressing an antibody directed against it rather than mutating the protein itself. The concept of using an antibody directed against phospholamban to increase SERCA activity has been investigated previously in isolated SR vesicles and permeabilized myocytes (10, 11) . As these antibodies do not pass the sarcolemma, they are not readily applicable to use in vivo. The use of advanced phage display technologies has allowed us to obtain the cDNA information for both IgY light and heavy chains fused into a functional single chain antibody (PLN-Ab).
Immunoblots clearly indicate that recombinant PLN-Ab binds to phospholamban, giving a response similar to the well-characterized anti-phospholamban antibody 2D12 (11) . We further characterized the interactions of PLN-Ab with phospholamban through the use of a FRET assay. A chimeric protein was created which featured the phosphor-acceptor and hinge regions of phospholamban flanked by cyano (C) and yellow (Y) fluorescent protein moieties. This method is based on the principle that alterations in conformation of the chimeric protein will alter the energy transfer between CFP and YFP, yielding changes in the Y/C emission ratio. For neonatal myocytes transfected with CcPlnY, the Y/C ratio diminished with the addition of isoproterenol. This most likely results from phosphorylation of CcPlnY protein kinase A system to yield a more extended conformation of CcPlnY. For in vitro experiments, similar reductions in Y/C fluorescence were obtained by adding PLN-Ab, the anti-phospholamban antibody 2D12, or the catalytic subunit of protein kinase A. All of these treatments (PLN-Ab, 2D12, PKA) produced similar alterations in phospholamban and have positive effects on SERCA-mediated calcium uptake. The action of PLN-Ab in stimulating calcium uptake by SR vesicles isolated from HEK 293 cells (cotransfected with SERCA and phospholamban) supports this view. The interaction of PLN-Ab with phospholamban is therefore likely to induce a conformational change in phospholamban similar to that elicited by PKA-mediated phosphorylation, resulting in a release of phospholamban-mediated inhibition of SERCA activity.
Although we were able to demonstrate the utility of PLN-Ab in stimulating Ca 2+ uptake in vitro, it was uncertain that a protein of avian origin would affect Ca 2+ uptake in vivo. Cardiac myocytes were able to express PLN-Ab as a cytosolic protein, which had the same molecular weight as the bacterially expressed protein, suggesting that no major modification or degradation had occurred. A pattern of expression consistent with association with the sarcoplasmic reticulum was observed in both neonatal rat and adult mouse cardiac myocyte (21) . Expression of PLN-Ab did not appear to affect synthesis and translocation of endogenous phospholamban, as shown by unchanged phospholamban levels.
To measure the effects of PLN-Ab on cardiac calcium handling, rat neonatal cardiac myocytes were transfected with a plasmid containing PLN-Ab. As expected, PLN-Ab resulted in a significantly accelerated the decay of the calcium transient. In adult mouse myocytes first infected in vivo, and then isolated by collagenase digestion, the expression of PLN-Ab also accelerated the decay of the calcium transient. Significantly, PLN-Ab expression led to an increase in contractile parameters in isolated myocytes, including an increase in fractional shortening and increased rate of relaxation. Adenoviral gene transfer of PLN-Ab to adult rat hearts led to a significant acceleration of relaxation and a substantial decrease of end-diastolic pressure. Although the effects of PLN-Ab were apparent in both isolated myocytes and the intact heart of normal animals, we wanted to determine if PLN-Ab would be beneficial in a disease state with depressed contractility. Diabetes leads to a decrease in SERCA activity and expression, especially in relation to phospholamban which shows an increased expression relative to SERCA and which may be in a less phosphorylated state (31-34). Adenovirally mediated expression of PLN-Ab improved contractility in diabetic mice. This effect was observed in measurements made on both ex vivo isolated hearts and in vivo through the use of echo cardiography. The improvement in function was not related to a change in SERCA or phospholamban expression as a result of the treatment. Combined, these results suggest that PLN-Ab, through its interaction with phospholamban, increases the rate of Ca 2+ sequestration by the SR and in so doing increases contractility.
The results presented in this study are consistent with PLN-Ab mediating its effects through interaction with phospholamban, increasing SERCA activity. This strategy involves the expression of a novel protein and avoids direct modification of phospholamban through mutation. However, although PLN-Ab appears to mediate its effect through phospholamban, due to its avian origin we cannot exclude the possibility of its interacting with other proteins within the cardiac myocyte. Similarly, the long-term consequences of expressing such a foreign protein in the heart are unknown. We plan to address these questions through the generation of a transgenic mouse overexpressing PLN-Ab. Commercially available phospholamban antibody (2D12) was used in parallel. Visualization of phospholamban by PLNAb was achieved with a biotinylated antibody directed against the HA-tag followed by a streptavidin-linked horseradish peroxidase. C) Recombinant PLN-Ab and 2D12 activate SR calcium uptake (free Ca, 20 nM) to a similar extend (n=4/group). An unrelated recombinant single chain antibody (scFab) used as a control showed a small stimulatory effect. Ab to the heart was performed in 11 rats while 7 rats were treated with a control adenovirus (no transgene). Upper figures represent pressure traces taken in vivo, while lower figures represent the first derivative of pressure with respect to time. Maximum velocity of cardiac relaxation (-dP/dt) was increased by 14% and end-diastolic pressure was decreased by 50% in PLN-Ab treated hearts. *P < 0.05. expression (HA tag) in the heart of diabetic mice. Maximum rate of relaxation (B, -dP/dt) and contraction (C, +dP/dt) and peak systolic pressure (D) in isolated hearts from nondiabetic and diabetic mice treated with streptozotocin. Mice were either untreated (nondiabetic n=12, and diabetic n=17 groups) or treated with either PLN-Ab (diabetic PLN-Ab Adv, n=8) or control adenovirus (diabetic control Adv, n =6). *Significant difference from nondiabetic group (P< 0.05); # significant difference with respect to diabetic mice treated with control adenovirus. 
